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The Yale Journal of Biology and Med-
icine brings you our December 2011 issue
with a focus on immunobiology. A dynamic
and rapidly changing field, immunobiology
is a discipline of significant relevance to
medicine. For example, the 2011 Nobel
Prize  in  Physiology  or  Medicine  was
awarded to three researchers for two piv-
otal discoveries in immunobiology: the in-
nate  immune  system  and  the  role  of
dendritic cells in adaptive immunity.
Yale University’s immunobiology de-
partment is one of the most productive and
prolific research programs in the world. Es-
tablished in 1988, the department quickly
rose to prominence in the 1990s, led by the
late Charles Janeway [1]. In the following
decade, the department made major contri-
butions to the scientific understanding of
immunity. Janeway and Ruslan Medzhitov
discovered Toll-like receptors, a class of
molecules that permit the innate immune
system to instruct the adaptive immune sys-
tem [2,3]. Richard Flavell studied the role
of cytokine signaling molecules, including
TGFʲ, IL-6, and CD40/CD40L, in lym-
phocyte  biology  [4,5].  Peter  Cresswell
characterized the mechanisms by which
proteins are processed into peptides for
presentation to the immune system [6,7].
To this day, Yale Immunobiology continues
to lead the field.
One of the earliest discoveries in im-
munobiology was Edward Jenner’s finding
in 1796 that inoculating individuals with
Vaccinia virus could make them resistant to
smallpox, a deadly scourge. Jenner, how-
ever, had no understanding of why inocu-
lation worked, nor did he have the tools to
study these mechanisms. Today, we not
only know the mechanisms by which inoc-
ulation and vaccination work, but are be-
ginning to design vaccines that train the
immune system against novel targets. De-
spite Jenner’s revolutionary experiment in
1796, immunobiology as we know it today
is a relatively new field. Most major ad-
vances in our understanding of the human
immune system have occurred over the past
50 years with the advent of more advanced
molecular and genetic methods in biology.
Research being conducted now could
bring new therapies to the forefront, includ-
ing  those  to  treat  autoimmune  diseases,
metastatic cancer, and chronic viral diseases.
Furthermore, innovations in immunobiol-
ogy, such as monoclonal antibodies, are used
as  both  therapies  and  universal  research
tools. The reviews in this issue cover a vari-
ety of topics, including the exciting clinical
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translation of groundbreaking basic science
research in the 1990s. 
Case reviews the regulation of a key
proinflammatory pathway that participates
in the assembly of the inflammasome, and
is a critical mediator of cytokine secretion
and induction of cell death. 
Chang  describes  current  research  on
TRegs,  a  regulatory  T-cell  subset  that  are
CD4+FoxP3+, and novel approaches to pre-
vent transplant rejection. Sadanand looks at
modern-day challenges to vaccine develop-
ment and distribution, including the creation
of vaccines against pervasive pathogens such
as tuberculosis and malaria, and the logistics
of distributing vaccines to developing na-
tions. Smith examines novel approaches to
therapy for tuberculosis. 
In the past 20 years, breakthroughs in
immunobiology  methods  and  knowledge
have paved the way toward treatments for
immunotherapy of cancer, one of the dead-
liest killers in the United States. In particu-
lar, immunotherapy gives treatment options
to those with metastatic disease, offering
significant extension of life and improved
quality of life for those with stage IV can-
cer.  These  novel  therapies  were  derived
from  the  translation  of  basic  science  re-
search and are a promising look at the pos-
sibilities on the horizon for the future of
medicine.
Dimberu  and  Leonhardt  review  im-
munologic therapies for cancer, ranging from
high-dose IL-2 to more recent advances, in-
cluding adoptive T-cell transfer, cancer vac-
cines, and monoclonal antibodies. Mansh
describes in detail the development of ipili-
mumab, the first monoclonal antibody that
augments  the  immune  response  to  fight
metastatic cancer. Chamarthy, Williams, and
Moadel describe the clinical efficacy and use
of Zevalin and Bexxar, radioisotope-conju-
gated monoclonal antibodies, for lymphoma
and explain the challenges behind expanding
radioimmunotherapy to solid tumors. Flies,
Sandler, and Chen review the translational
and clinical application of monoclonal anti-
bodies directed against PD-1/B7-H1, an im-
munomodulatory pathway manipulated by
many cancers to evade the immune system.
It is truly an exciting time for students,
scientists,  and  physicians  to  become  in-
volved in immunobiology research. Whether
it’s the pathophysiology of an autoimmune
condition, the mechanisms by which para-
sites evade immune recognition, or the role
of macrophages in the formation of athero-
sclerotic plaques, an understanding of the
immune system is necessary to appreciate
the full complexity of many human diseases.
We hope you enjoy this issue and consider
participating in this rapidly evolving field
that promises to transform the future of bi-
ology and medicine.
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